Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols

Massimo Breccia, Clara Minotti, Roberto Latagliata, Giuseppina Loglisci, Adriano Salaroli, Maria Giovanna Loglisci, Francesco Lo-Coco

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Despite the impressive results obtained with standard chemotherapy, approximately 20% of acute promyelocytic leukemia (APL) patients undergo disease relapse thereby requiring salvage therapy. Few data is available on long-term prognosis in relation to time to complete remission (CR): we reviewed 142 patients treated with AIDA protocols and we found that 42 out of 142 (29.6%) patients achieved CR after 35 days (median time, 42 days). No significant differences in presenting features, including FAB subtype, type of PML/RARA transcript and relapse risk at presentation between the two patient groups achieving CR > or

Original languageEnglish
Pages (from-to)383-385
Number of pages3
JournalLeukemia Research
Volume37
Issue number4
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Recurrence
Salvage Therapy
Therapeutics
Drug Therapy
AIDA protocol

Keywords

  • APL
  • ATRA
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols. / Breccia, Massimo; Minotti, Clara; Latagliata, Roberto; Loglisci, Giuseppina; Salaroli, Adriano; Loglisci, Maria Giovanna; Lo-Coco, Francesco.

In: Leukemia Research, Vol. 37, No. 4, 04.2013, p. 383-385.

Research output: Contribution to journalArticle

Breccia, Massimo ; Minotti, Clara ; Latagliata, Roberto ; Loglisci, Giuseppina ; Salaroli, Adriano ; Loglisci, Maria Giovanna ; Lo-Coco, Francesco. / Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols. In: Leukemia Research. 2013 ; Vol. 37, No. 4. pp. 383-385.
@article{d4ff1ccb0be24aeaa3b9524d1d0d316f,
title = "Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols",
abstract = "Despite the impressive results obtained with standard chemotherapy, approximately 20{\%} of acute promyelocytic leukemia (APL) patients undergo disease relapse thereby requiring salvage therapy. Few data is available on long-term prognosis in relation to time to complete remission (CR): we reviewed 142 patients treated with AIDA protocols and we found that 42 out of 142 (29.6{\%}) patients achieved CR after 35 days (median time, 42 days). No significant differences in presenting features, including FAB subtype, type of PML/RARA transcript and relapse risk at presentation between the two patient groups achieving CR > or",
keywords = "APL, ATRA, Prognosis",
author = "Massimo Breccia and Clara Minotti and Roberto Latagliata and Giuseppina Loglisci and Adriano Salaroli and Loglisci, {Maria Giovanna} and Francesco Lo-Coco",
year = "2013",
month = "4",
doi = "10.1016/j.leukres.2012.11.014",
language = "English",
volume = "37",
pages = "383--385",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "4",

}

TY - JOUR

T1 - Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols

AU - Breccia, Massimo

AU - Minotti, Clara

AU - Latagliata, Roberto

AU - Loglisci, Giuseppina

AU - Salaroli, Adriano

AU - Loglisci, Maria Giovanna

AU - Lo-Coco, Francesco

PY - 2013/4

Y1 - 2013/4

N2 - Despite the impressive results obtained with standard chemotherapy, approximately 20% of acute promyelocytic leukemia (APL) patients undergo disease relapse thereby requiring salvage therapy. Few data is available on long-term prognosis in relation to time to complete remission (CR): we reviewed 142 patients treated with AIDA protocols and we found that 42 out of 142 (29.6%) patients achieved CR after 35 days (median time, 42 days). No significant differences in presenting features, including FAB subtype, type of PML/RARA transcript and relapse risk at presentation between the two patient groups achieving CR > or

AB - Despite the impressive results obtained with standard chemotherapy, approximately 20% of acute promyelocytic leukemia (APL) patients undergo disease relapse thereby requiring salvage therapy. Few data is available on long-term prognosis in relation to time to complete remission (CR): we reviewed 142 patients treated with AIDA protocols and we found that 42 out of 142 (29.6%) patients achieved CR after 35 days (median time, 42 days). No significant differences in presenting features, including FAB subtype, type of PML/RARA transcript and relapse risk at presentation between the two patient groups achieving CR > or

KW - APL

KW - ATRA

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84875381625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875381625&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.11.014

DO - 10.1016/j.leukres.2012.11.014

M3 - Article

VL - 37

SP - 383

EP - 385

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 4

ER -